Cancer Control

The changing landscape of second primary malignancies in multiple myeloma: A SEER population-based study between two therapeutic eras

Frontiers in Digital Health

Shaping the future of multiple myeloma with artificial intelligence and digital twins: from concept to clinic

International Journal of Hematology

Anti-CD38-based quadruplet versus triplet induction regimens in transplant-ineligible newly diagnosed multiple myeloma: a systematic review and meta-analysis

Frontiers in Oncology

Morphology-based cytogenetic risk prediction in multiple myeloma from bone marrow smears

Frontiers in Immunology

Tailored strategies for improved control of CAR-T cells in multiple myeloma

Molecular Therapy

CAR-modified marrow infiltrating lymphocytes efficiently target malignant plasma cells with very low antigen density

Frontiers in Oncology

Ocular toxicities of targeted therapies and immunotherapies in hematologic malignancies

Journal of Clinical and Experimental Hematopathology

Pseudoprogression of extramedullary lesions during elranatamab therapy in relapsed or refractory multiple myeloma

Annals of Hematology

Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study

EClinicalMedicine

Temporal trends in progression risk in smoldering myeloma: A systematic review